Yujiro S. Hata - Mar 13, 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Matthew Kowalsky as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Mar 13, 2025
Transactions value $
$0
Form type
4
Date filed
3/14/2025, 05:35 PM
Previous filing
Feb 28, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +15.7K $0.00 15.7K Mar 13, 2025 Common Stock 15.7K $6.83 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders.

Remarks:

Exhibit 24 Power of Attorney filed herewith.